Journal of ethnopharmacology

A sugar from Ganoderma lucidum reduces inflammation in Parkinson's disease by improving gut balance and blocking a key immune signaling pathway

Updated

Abstract

A purified glucan, GLPZ-2, exhibits significant anti-inflammatory effects on Parkinson's disease.

  • GLPZ-2 has a triple helical structure primarily composed of various sugar linkages.
  • In a mouse model of Parkinson's disease, GLPZ-2 improved motor symptoms and reduced pathological damage.
  • Treatment with GLPZ-2 decreased the brain protein levels of α-Syn, IL-6, IL-1β, and TNF-α.
  • GLPZ-2 regulated gut microbiota and fecal metabolites, restoring them to normal levels.
  • GLPZ-2 increased the content of short-chain fatty acids (SCFAs) in the intestine.
  • The compound inhibited the TLR4/MyD88/NF-κB signaling pathway in intestinal cells.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free